Insights into the pharmacokinetic properties of antitubercular drugs

References

• World Health Organization. Global tuberculosis report [Internet]; 2014 [cited 2015 Aug 20]. Available from: http://www.who.int/tb/publications/global_report/en
   Google Scholar
• Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014;12(3):159–167.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of tuberculosis guidelines [Internet]; 2010. [cited 2015 Aug 25]. Available from: http://www.who.int/tb/publications/2010/9789241547833/en
   Google Scholar
• Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12(5):388–404.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320–1330.
   PubMed Web of Science ®Google Scholar
• Douglas JG, McLeod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet. 1999;37(2):127–146.
   PubMed Web of Science ®Google Scholar
• Vaddady PK, Lee RE, Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med Chem. 2010;2(8):1355–1369.
   PubMed Web of Science ®Google Scholar
• Mariappan T, Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int J Tuberc Lung Dis. 2003;7(8):797–803.
   PubMed Web of Science ®Google Scholar
• Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4(6):401–422.
   PubMed Web of Science ®Google Scholar
• Woo J, Cheung W, Chan R, et al. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and α-1-acid glycoprotein. Clin Biochem. 1996;29(2):175–177.
   PubMed Web of Science ®Google Scholar
• Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–2183.
   PubMed Web of Science ®Google Scholar
• Nitti V, Virgilio R, Patricolo MR, et al. Pharmacokinetic study of intravenous rifampicin. Chemother. 1977;23(1):1–6.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40(5):327–341.
   PubMed Web of Science ®Google Scholar
• Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978;3(2):108–127.
   PubMed Web of Science ®Google Scholar
• Fahimi F, Tabarsi P, Kobarfard F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17(12):1602–1606.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854.
   PubMed Web of Science ®Google Scholar
• Lacroix C, Hoang TP, Nouveau J, et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol. 1989;36(4):395–400.
   PubMed Web of Science ®Google Scholar
• Chen MM, Lee CS, Perrin JH. Absorption and disposition of ethambutol in rabbits. J Pharm Sci. 1984;73(8):1053–1055.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43(3):568–572.
   PubMed Web of Science ®Google Scholar
• Lee CS, Brater DC, Gambertoglio JG, et al. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm. 1980;8(4):335–346.
   PubMedGoogle Scholar
• Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1989;33(8):1237–1241.
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis. 1996;22 Suppl 1:S15–21; discussion S21–22.
   PubMed Web of Science ®Google Scholar
• Zhu M, Nix DE, Adam RD, et al. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacother. 2001;21(8):891–897.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet. 1989;16(2):74–85.
   PubMed Web of Science ®Google Scholar
• Anonymous. Ethionamide (Edinb). Tuberculosis. 2008;88(2):106–108.
   PubMedGoogle Scholar
• Slatter JG, Adams LA, Bush EC, et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica. 2002;32(10):907–924.
   PubMed Web of Science ®Google Scholar
• Zhu M, Burman WJ, Jaresko GS, et al. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacother. 2001;21(9):1037–1045.
   PubMed Web of Science ®Google Scholar
• Boxer GE, Jelinek VC, Edison AO. Streptomycin; clearance and binding to protein. J Pharmacol Exp Ther. 1949;97(1):93–104.
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37(5):385–398.
   PubMed Web of Science ®Google Scholar
• Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis. 1991;10(10):807–812.
   PubMed Web of Science ®Google Scholar
• Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther. 1997;61(6):641–648.
   PubMed Web of Science ®Google Scholar
• Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2001;5(6):533–538.
   PubMed Web of Science ®Google Scholar
• Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996;22(5):443–446.
   PubMed Web of Science ®Google Scholar
• Leroy A, Borsa F, Humbert G, et al. The pharmacokinetics of ofloxacin in healthy adult male volunteers. Eur J Clin Pharmacol. 1987;31(5):629–630.
   PubMed Web of Science ®Google Scholar
• Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother. 1987;31(2):156–160.
   PubMed Web of Science ®Google Scholar
• Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001–1007.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Park JG, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012;59(5):455–462.
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69(9):2310–2318.
   PubMed Web of Science ®Google Scholar
• Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009;53(9):3720–3725.
   PubMed Web of Science ®Google Scholar
• van den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849–862.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Alffenaar J-WC, Centis R, et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis. 2015;32:101–104.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997;49(4):403–449.
   PubMed Web of Science ®Google Scholar
• Kjellsson MC, Via LE, Goh A, et al. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother. 2012;56(1):446–457.
   PubMed Web of Science ®Google Scholar
• Lurie MB, Dannenberg Jr AM. Stages in the pathogenesis of human and rabbit tuberculosis. In: Dannenberg Jr AM, editor. Pathogenesis of human pulmonary tuberculosis. Washington, DC: American Society of Microbiology Press; 2006. p. 22–23.
   Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61(2):235–237.
   PubMed Web of Science ®Google Scholar
• Argyrou A, Jin L, Siconilfi-Baez L, et al. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochem. 2006;45(47):13947–13953.
   PubMed Web of Science ®Google Scholar
• Nishida CR, Ortiz de Montellano PR. Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases. Chem Biol Interact. 2011;192(1–2):21–25.
   PubMed Web of Science ®Google Scholar
• Singh R, Manjunatha U, Boshoff HIM, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–1395.
   PubMed Web of Science ®Google Scholar
• Egelund EF, Peloquin CA. Current issues in tuberculosis pharmacokinetics. In: Donald PR, van Helden PD, editors. Antituberculosis chemotherapy. Vol. 40. Prog Respir Res. Basel: Karger; 2011. p. 153–160.
   Google Scholar
• Hall RG, Swancutt MA, Meek C, et al. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2012;56(3):1502–1507.
   PubMed Web of Science ®Google Scholar
• Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis. 2004;8(11):1360–1367.
   PubMed Web of Science ®Google Scholar
• Lee SY, Jang H, Lee JY, et al. Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014;229(1):33–40.
   PubMed Web of Science ®Google Scholar
• Namdar R, Ebert SC, Peloquin C. Drugs for tuberculosis. In: Piscitelli S, Rodvold K, editors. Drug interactions in infectious diseases. Totowa (NJ): Humana Press; 2001. p. 109–120.
   Google Scholar
• Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591–593.
   PubMed Web of Science ®Google Scholar
• Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther. 2015;98(4):387–393.
   PubMed Web of Science ®Google Scholar
• Rao KV, Kailasam S, Menon NK, et al. Inactivation of isoniazid by condensation in a syrup preparation. Bull World Health Organ. 1971;45(5):625–632.
   PubMed Web of Science ®Google Scholar
• Schaaf H, Parkin D, Seifart H, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90(6):614–618.
   PubMed Web of Science ®Google Scholar
• Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther. 1993;54(6):612–620.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jiao Y, Wei YH, et al. Effects of pyridoxine on the intestinal absorption and pharmacokinetics of isoniazid in rats. Eur J Drug Metab Pharmacokinet. 2013;38(1):5–13.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1984;9(6):511–544.
   PubMed Web of Science ®Google Scholar
• Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45(2):382–392.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis. 2002;6(11):952–958.
   PubMed Web of Science ®Google Scholar
• Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis. 1999;3(2):133–137.
   PubMed Web of Science ®Google Scholar
• Graham SM, Bell DJ, Nyirongo S, et al. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50(2):407–413.
   PubMed Web of Science ®Google Scholar
• Lacroix C, Guyonnaud C, Chaou M, et al. Interaction between allopurinol and pyrazinamide. Eur Respir J. 1988;1(9):807–811.
   PubMed Web of Science ®Google Scholar
• Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ. 2002;167(2):131–136.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Dona CSWS, Meek C, et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother. 2009;53(8):3197–3204.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819–850.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693–705.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–3788.
   PubMed Web of Science ®Google Scholar
• Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–2124.
   PubMed Web of Science ®Google Scholar
• Pargal A, Rani S. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int J Tuberc Lung Dis. 2001;5(1):70–79.
   PubMed Web of Science ®Google Scholar
• Smythe W, Khandelwal A, Merle C, et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother. 2012;56(4):2091–2098.
   PubMed Web of Science ®Google Scholar
• Jadhav MV, Sathe AG, Deore SS, et al. Tissue concentration, systemic distribution and toxicity of clofazimine-an autopsy study. Indian J Pathol Microbiol. 2004;47(2):281–283.
   PubMedGoogle Scholar
• Mehta J, Gandhi IS, Sane SB, et al. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases. Lepr Rev. 1986;57 Suppl 3:67–76.
   PubMedGoogle Scholar
• Wilson JG. Present status of drugs as teratogens in man. Teratology. 1973;7(1):3–15.
   PubMedGoogle Scholar
• Jenner PJ, Ellard GA, Gruer PJ, et al. A comparison of the blood levels and urinary excretion of ethionamide and prothionamide in man. J Antimicrob Chemother. 1984;13(3):267–277.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–1442.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos. 2001;29(8):1136–1145.
   PubMed Web of Science ®Google Scholar
• Panomvana D, Kiatjaroensin SA, Phiboonbanakit D. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime. Clin Pharmacokinet. 2007;46(10):859–866.
   PubMed Web of Science ®Google Scholar
• Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25 Suppl A:73–82.
   PubMed Web of Science ®Google Scholar
• Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25(3):189–204.
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432–442.
   PubMed Web of Science ®Google Scholar
• Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51(2):576–582.
   PubMed Web of Science ®Google Scholar
• Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc). 2000;36(4):229–244.
   PubMed Web of Science ®Google Scholar
• Lounis N, Bentoucha A, Truffot-Pernot C, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother. 2001;45(12):3482–3486.
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1131–1134.
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587.
   PubMed Web of Science ®Google Scholar
• Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One. 2013;8(7):e67030.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642–1651.
   PubMed Web of Science ®Google Scholar
• Wong FA, Flor SC. The metabolism of ofloxacin in humans. Drug Metab Dispos. 1990;18(6):1103–1104.
   PubMed Web of Science ®Google Scholar
• Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med. 1989;87(5, Supplement 1):S76–S81.
   PubMed Web of Science ®Google Scholar
• Working Group on New Drugs. Stop TB Partnership. 2015 [cited 2015 Dec 1]. Available from: http://www.newtbdrugs.org/pipeline.php
   Google Scholar
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223–227.
   PubMed Web of Science ®Google Scholar
• Huitric E, Verhasselt P, Andries K, et al. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51(11):4202–4204.
   PubMed Web of Science ®Google Scholar
• Petrella S, Cambau E, Chauffour A, et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother. 2006;50(8):2853–2856.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. N Eng J Med. 2014;371(8):723–732.
   PubMed Web of Science ®Google Scholar
• Anonymous. LL-3858. Tuberculosis (Edinb). 2008;88(2):126.
   PubMedGoogle Scholar
• Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949–954.
   PubMed Web of Science ®Google Scholar
• Hittel N. Open forum II on key issues in TB drug development. London, 2006 [cited 2015 Dec 10]. Available from: http://www.kaisernetwork.org/health_cast/uploaded_files/Hittel,_Norbert_(12-12)_OPC_67683.pdf
   Google Scholar
• Sasaki H, Haraguchi Y, Itotani M, et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J Med Chem. 2006;49(26):7854–7860.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.
   PubMed Web of Science ®Google Scholar
• Choi KP, Bair TB, Bae YM, et al. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J Bacteriol. 2001;183(24):7058–7066.
   PubMed Web of Science ®Google Scholar
• Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol. 2002;184(9):2420–2428.
   PubMed Web of Science ®Google Scholar
• Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005;49(6):2294–2301.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005;49(6):2289–2293.
   PubMed Web of Science ®Google Scholar
• Winter H, Ginsberg A, Egizi E, et al. Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. Antimicrob Agents Chemother. 2013;57(11):5516–5520.
   PubMed Web of Science ®Google Scholar
• Dogra M, Palmer BD, Bashiri G, et al. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver. Br J Pharmacol. 2011;162(1):226–236.
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(4):1522–1524.
   PubMed Web of Science ®Google Scholar
• de Jonge MR, Koymans LHM, Guillemont JEG, et al. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. Proteins. 2007;67(4):971–980.
   PubMed Web of Science ®Google Scholar
• Jia L, Noker PE, Coward L, et al. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006;147(5):476–485.
   PubMed Web of Science ®Google Scholar
• Chen P, Gearhart J, Protopopova M, et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother. 2006;58(2):332–337.
   PubMed Web of Science ®Google Scholar
• Anonymous. SQ109. Tuberculosis (Edinb). 2008;88(2):159–161.
   PubMedGoogle Scholar
• Sacksteder KA, Protopopova M, Barry CE, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 2012;7(7):823–837.
   PubMed Web of Science ®Google Scholar
• Horwith G, Protopopova M, Lyer L, et al. Drug-drug interaction studies of SQ109 with first-line anti-TB drugs. 1st Int Workshop Clin Pharmacol Tuberculosis Drugs; 2008; Toronto, Canada; Abstract no. 16.
   Google Scholar
• Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis [Internet]. 2013 [cited 2015 Nov 25]. Available from: http://www.cdc.gov/tb/publications/guidelines/hiv_aids.htm
   Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657–1663.
   PubMed Web of Science ®Google Scholar
• Ngaimisi E, Mugusi S, Minzi O, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther. 2011;90(3):406–413.
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40(10):1481–1491.
   PubMed Web of Science ®Google Scholar